Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Kavita Venugcpal Nair

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-2635

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wilson AM, Lundgren KB, Schierman B, Mante A, Lien A, Benish SM, Esper GJ, Nair KV, Ney JP. Examining the National Representativeness of the Axon Registry: A Neurology-Specific Patient Registry. Neurology. 2023 09 12; 101(11):e1167-e1177. PMID: 37487753.
      View in: PubMed
    2. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz?lez J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588. PMID: 36811392.
      View in: PubMed
    3. Nair KV. Role of the Bruton tyrosine kinase pathway in multiple sclerosis. Am J Manag Care. 2022 Dec; 28(16 Suppl):S323-S328. PMID: 36548523.
      View in: PubMed
    4. de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137. PMID: 33692164.
      View in: PubMed
    5. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454. PMID: 33045496.
      View in: PubMed
    6. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease. J Manag Care Spec Pharm. 2020 May; 26(5):575-585. PMID: 32347176.
      View in: PubMed
    7. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21. PMID: 26888980.
      View in: PubMed
    8. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205. PMID: 24458545.
      View in: PubMed
    9. Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013 Apr; 35(4):385-398.e1. PMID: 23541707.
      View in: PubMed
    10. Nair KV, Naim AB, Draaghtel K, Van Den Bos J. Work absences and expenditures for employees with autoimmune inflammatory diseases. J Occup Environ Med. 2012 Oct; 54(10):1268-74. PMID: 22995815.
      View in: PubMed
    11. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012 Nov; 51(11):2004-12. PMID: 22829689.
      View in: PubMed
    12. Abbott ZI, Nair KV, Allen RR, Akuthota VR. Utilization characteristics of spinal interventions. Spine J. 2012 Jan; 12(1):35-43. PMID: 22138113.
      View in: PubMed
    13. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011 Sep 14; 9:13. PMID: 21917132.
      View in: PubMed
    14. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98. PMID: 21651327.
      View in: PubMed
    15. Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan. J Health Care Finance. 2011; 38(2):38-53. PMID: 22372031.
      View in: PubMed
    16. Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Prescription co-pay reduction program for diabetic employees. Popul Health Manag. 2010 Oct; 13(5):235-45. PMID: 20879904.
      View in: PubMed
    17. Bhardwaja B, Carroll N, Korner E, Nair KV. Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD. Am Health Drug Benefits. 2009 Sep; 2(6):242-50. PMID: 25126297.
      View in: PubMed
    18. Nair KV, Park J, Wolfe P, Saseen JJ, Allen RR, Ganguly R. Consumer-driven health plans: impact on utilization and expenditures for chronic disease sufferers. J Occup Environ Med. 2009 May; 51(5):594-603. PMID: 19369897.
      View in: PubMed
    19. Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin. 2009 Feb; 25(2):303-14. PMID: 19192975.
      View in: PubMed
    20. Nair KV, Miller K, Saseen J, Wolfe P, Allen RR, Park J. Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization. Am Health Drug Benefits. 2009 Jan; 2(1):14-24. PMID: 25126268.
      View in: PubMed
    21. Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother. 2006 Jan; 40(1):124-7. PMID: 16368926.
      View in: PubMed
    22. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care. 2005 Jun; 11(6):374-82. PMID: 15974556.
      View in: PubMed
    23. Nair KV, Sullivan PW. Therapeutic and economic consequences of OTC loratadine. Ann Pharmacother. 2004 Jan; 38(1):169-71. PMID: 14742815.
      View in: PubMed
    24. Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther. 2003 Nov; 25(11):2936-57. PMID: 14693317.
      View in: PubMed
    25. Nair KV. Do consumers' attitudes predict prescription purchasing behavior? Manag Care Interface. 2003 Jun; 16(6):22-7, 55. PMID: 12841073.
      View in: PubMed
    26. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003 Mar-Apr; 9(2):123-33. PMID: 14613341.
      View in: PubMed
    27. Nair KV, Ganther JM, Valuck RJ, McCollum MM, Lewis SJ. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states. J Manag Care Pharm. 2002 Nov-Dec; 8(6):477-91. PMID: 14613381.
      View in: PubMed
    28. Nair KV. Evaluation of health and pharmacy benefit information in health plan information packages. Manag Care Interface. 2001 Dec; 14(12):51-4. PMID: 11794843.
      View in: PubMed
    Nair's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)